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Summary
Background Findings from randomised trials have shown a higher early risk of stroke after carotid artery stenting 
than after carotid endarterectomy. We assessed whether white-matter lesions aﬀ ect the perioperative risk of stroke in 
patients treated with carotid artery stenting versus carotid endarterectomy. 
Methods Patients with symptomatic carotid artery stenosis included in the International Carotid Stenting Study 
(ICSS) were randomly allocated to receive carotid artery stenting or carotid endarterectomy. Copies of baseline brain 
imaging were analysed by two investigators, who were masked to treatment, for the severity of white-matter lesions 
using the age-related white-matter changes (ARWMC) score. Randomisation was done with a computer-generated 
sequence (1:1). Patients were divided into two groups using the median ARWMC. We analysed the risk of stroke 
within 30 days of revascularisation using a per-protocol analysis. ICSS is registered with controlled-trials.com, 
number ISRCTN 25337470. 
Findings 1036 patients (536 randomly allocated to carotid artery stenting, 500 to carotid endarterectomy) had baseline 
imaging available. Median ARWMC score was 7, and patients were dichotomised into those with a score of 7 or more 
and those with a score of less than 7. In patients treated with carotid artery stenting, those with an ARWMC score of 7 
or more had an increased risk of stroke compared with those with a score of less than 7 (HR for any stroke 2·76, 
95% CI 1·17–6·51; p=0·021; HR for non-disabling stroke 3·00, 1·10–8·36; p=0·031), but we did not see a similar 
association in patients treated with carotid endarterectomy (HR for any stroke 1·18, 0·40–3·55; p=0·76; HR for 
disabling or fatal stroke 1·41, 0·38–5·26; p=0·607). Carotid artery stenting was associated with a higher risk of stroke 
compared with carotid endarterectomy in patients with an ARWMC score of 7 or more (HR for any stroke 2·98, 
1·29–6·93; p=0·011; HR for non-disabling stroke 6·34, 1·45–27·71; p=0·014), but there was no risk diﬀ erence in 
patients with an ARWMC score of less than 7.
Interpretation The presence of white-matter lesions on brain imaging should be taken into account when selecting 
patients for carotid revascularisation. Carotid artery stenting should be avoided in patients with more extensive 
white-matter lesions, but might be an acceptable alternative to carotid endarterectomy in patients with less extensive 
lesions.
Funding Medical Research Council, the Stroke Association, Sanoﬁ -Synthélabo, the European Union Research 
Framework Programme 5.
Background
Findings from randomised controlled trials comparing 
carotid artery stenting with carotid endarterectomy 
have consistently shown that, in patients with 
symptomatic carotid stenosis, carotid artery stenting is 
associated with a higher risk of periprocedural stroke or 
death than carotid endarterectomy.1–4 Findings from a 
systematic review of 11 randomised controlled trials 
showed a 70% increase in the risk of stenting compared 
with endarterectomy in terms of the occurrence of any 
stroke or death between randomisation and 30 days 
after treatment in symptomatic patients (odds ratio 
1·72, 95% CI 1·29–2·31).5 A meta-analysis of individual 
patient data from the three European trials6 showed 
that the diﬀ erence in early stroke or death rates 
favouring carotid endarterectomy was attributable to 
the treatment of patients older than 70 years, and that 
in patients younger than 70 years there was no 
diﬀ erence in risk.5 Similar ﬁ ndings were reported in 
the North American trial.4 No other subgroup variable 
has consistently been shown to aﬀ ect the diﬀ erence in 
risk favouring carotid endarterectomy. However, 
ﬁ ndings from the trials also conﬁ rmed that carotid 
artery stenting avoids some of the other complications 
of carotid endarterectomy, especially cranial nerve 
injury and myocardial infarction, and has a lower rate 
of wound haematoma.5 Therefore, a better 
understanding of risk factors for procedural stroke 
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would help inform clinicians as to the best treatment 
option for their patients. 
That carotid artery stenting, and to a lesser extent carotid 
endarterectomy, can cause embolisation of thrombus or 
plaque debris from the carotid plaque during the 
revascularisation procedure is well recognised. We 
hypothesised that severe cerebral white-matter damage 
might render patients more vulnerable to the eﬀ ects of 
embolisation and therefore more likely to manifest stroke; 
furthermore, this increased risk might diﬀ er between 
carotid artery stenting and carotid endarterectomy. 
Abnormalities in white matter are a common ﬁ nding on 
CT and MRI scans of the brain.7–13 In 1987, Hachinski and 
colleagues proposed the term leukoaraiosis as a purely 
descriptive term for the presence of patchy diﬀ use changes 
in the periventricular cerebral white matter.12 Nowadays, 
the term white-matter lesions is more commonly used for 
the same ﬁ ndings. In most patients, these lesions are 
likely to be the consequence of degenerative changes in 
the deep perforating arterioles. In patients with stroke, the 
reported prevalence of white-matter lesions is between 4% 
and 44% on CT and up to 100% on MRI.7,9,10 Risk factors 
for the development of white-matter lesions include age 
and hypertension. 
Leukoaraiosis was associated with a higher perioperative 
risk of stroke or death in patients assigned to carotid 
endarterectomy in the North American Carotid 
Endarterectomy Trial (NASCET).14 Patients with 
widespread white-matter changes allocated to the best 
medical management group also had an increased risk of 
stroke or death. To the best of our knowledge, the eﬀ ect of 
white-matter lesions on the procedural risk of stroke and 
death in carotid stenting has hitherto not been investigated. 
We therefore investigated the eﬀ ect of leukoaraiosis on 
the risk of procedural complications in a large group of 
patients with recently symptomatic carotid disease 
randomised in the International Carotid Stenting Study.
Methods
Patients
The International Carotid Stenting Study (ICSS) is an 
international multicentre randomised clinical trial 
comparing carotid stenting and endarterectomy in 
patients with symptomatic carotid atheromatous stenosis. 
The ICSS protocol and the results of an interim analysis 
of the short-term outcome events within 120 days of 
randomisation are available elsewhere.3,15 Brieﬂ y, ICSS 
included patients older than 40 years with atherosclerotic 
carotid artery stenosis measuring 50% or more which had 
been symptomatic within the previous 12 months. 
Patients were excluded if they had major stroke with no 
useful recovery of function, were not suitable for 
endarterectomy for anatomical or medical reasons, or if 
the stenosis was considered unsuitable for stenting. For 
patients to be randomly assigned to treatment, the 
investigators had to be uncertain about which of the two 
treatment options would be best for the patient. 
All patients participating in ICSS provided written 
informed consent. Brain imaging by CT or MRI was 
needed before revascularisation. We included in this 
study of white-matter lesions all patients enrolled in 
ICSS in whom copies of the baseline CT or MRI done 
before carotid stenting or endarterectomy were available. 
Patients were excluded if no baseline brain imaging was 
available or if the quality of the images was poor.
ICSS was approved by the Northwest Multicentre 
Research Ethics Committee in the UK and participating 
centres had to obtain site-speciﬁ c approval from their 
local ethics committee. 
Randomisation and masking
Patients in the ICSS were randomly assigned in a one-to-
one ratio to receive carotid artery stenting or carotid 
endarterectomy. Randomisation was by telephone call or 
fax to a central computerised service and was stratiﬁ ed by 
centre with minimisation for sex, age, contralateral 
occlusion, and side of the randomised artery. Patients 
and investigators were not masked to treatment 
assignment. Patients were followed-up at 1 month after 
revascularisation by independent clinicians not directly 
involved in delivering the randomised treatment. 
Adjudication of the main outcome events was done by a 
masked independent outcome event committee.
Procedures
We deﬁ ned stroke as an acute disturbance of focal 
neurological function with symptoms lasting more than 
24 h, resulting from intracranial vascular disturbance. 
We included visual loss resulting from embolic or 
haemodynamic retinal ischaemia lasting more than 
24 h. We classiﬁ ed events leading to a modiﬁ ed Rankin 
score of 3 or greater for more than 30 days after onset as 
disabling; the remaining events were classiﬁ ed as 
non-disabling. Events leading to death within 30 days 
after onset were classiﬁ ed as fatal. We deﬁ ned a 
procedural event as one occurring within 30 days of 
treatment.
For the ICSS protocol see http://
www.ion.ucl.ac.uk/cavatas_icss/
downloads/icssprotocol.pdf
525 ARWMC score <7 511 ARWMC score ≥7
1649 procedure initiated per protocol
613 excluded
         603 no baseline brain imaging available
            10 baseline imaging of non-diagnostic 
                  quality
1036 included in ARWMC analysis
1713 patients randomised
Figure 1: Study proﬁ le
ARWMC=age-related white-matter changes.
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Anonymised diagnostic brain imaging before 
treatment was analysed at the central trial oﬃ  ce 
(University College London, Institute of Neurology, 
London, UK). Two investigators (JE and ID) trained in 
the analysis of white-matter lesions and masked to 
treatment and clinical outcome rated all images by 
consensus, using the age-related white-matter changes 
(ARWMC) score ﬁ rst introduced and validated for use 
in CT and MRI by Wahlund and colleagues.16 
White-matter lesions in the cerebral hemispheres and 
the brainstem were identiﬁ ed as poorly deﬁ ned 
hyperintensities 5 mm or larger in diameter on 
T2-weighted or FLAIR MRI images, or areas of poorly 
deﬁ ned hypodensity of 5 mm or larger in diameter on 
CT. We rated changes in the basal ganglia in the same 
manner. We rated the extent of white-matter disease on 
a 4-point scale in diﬀ erent brain regions on T2-weighted 
and FLAIR MRI images or on CT images: 0=no lesions 
(including symmetrical, well deﬁ ned caps or bands); 
1=focal lesions; 2=beginning conﬂ uence of lesions; 
3=diﬀ use involvement of the entire region, with or 
without involvement of U ﬁ bres.
We assessed the scans in ﬁ ve brain regions in each 
patient separately in the left and right hemispheres: the 
frontal area (the frontal lobe anterior to the central 
sulcus); the parieto-occipital area (the parietal and 
occipital lobes in combination); the temporal area (the 
temporal lobe, with a line from the posterior part of the 
Sylvian ﬁ ssure to the trigones of the lateral ventricles 
separating this area from the parieto-occipital area); the 
infratentorial area (which included the brainstem and 
cerebellum); and the basal ganglia region (which 
included the striatum, globus pallidus, thalamus, 
external capsules, and insula).
The total ARWMC score was then obtained by adding 
the scores for each brain region. Thus, the total ARWMC 
score ranged from 0 to 30. In addition to the rating of 
white-matter lesions, we recorded the presence of 
established cerebral infarcts. We did not record the 
location of these infarcts.
As expected in an international multicentre trial, 
various scanners and scanning protocols were used. 
We rated images available on ﬁ lm using standardised 
diagnostic grade light boxes. Digital imaging was 
reviewed using an open-source DICOM viewer software 
(OsiriX version 3.x). For patients in whom both CT and 
MRI had been done, we chose MRI for rating 
white-matter changes. 
Statistical analysis
We tested two hypotheses. The ﬁ rst was that, compared 
with less extensive white-matter lesions, more extensive 
white-matter lesions are associated with an increased 
risk of procedural stroke after treatment of carotid 
artery disease by either carotid artery stenting or carotid 
endarterectomy. The second was that the increase in 
procedural risk would diﬀ er in patients treated by 
carotid artery stenting compared with carotid 
endarterectomy. The plan to analyse imaging ﬁ ndings 
in relation to procedural risk was prespeciﬁ ed in the 
trial protocol. The details of the methods and statistical 
Carotid artery stenting 
(n=536)
Carotid endarterectomy 
(n=500)
p values
ARWMC score 
<7 (n=269)
ARWMC score 
≥7 (n=267)
ARWMC score 
<7 (n=256)
ARWMC score 
≥7 (n=244)
CT scan 164 (61%) 121 (45%) 165 (65%) 116 (48%) <0·0001
Age (mean [SD]; years) 68 (10) 73 (8) 66 (9) 74 (8) <0·0001
Women 68 (25%) 86 (32%) 75 (29%) 75 (31%) 0·330
Vascular risk factors
Cerebral infarct on 
baseline scan
120 (45%) 153 (57%) 110 (43%) 139 (57%) 0·0003
Hypertension 181 (68%) 199 (76%) 164 (64%) 180 (75%) 0·009
Systolic blood pressure 
(mean [SD]; mm Hg)
145 (25) 151 (25) 146 (23) 148 (24) 0·024
Diastolic blood pressure 
(mean [SD]; mm Hg)
80 (12) 80 (13) 79 (12) 79 (13) 0·716
Diabetes 61 (23%) 58 (26%) 51 (20%) 51 (21%) 0·861
Treated hyperlipidaemia 168 (63%) 165 (63%) 169 (66%) 154 (64%) 0·869
Cholesterol (mean [SD]; 
mmol/L)
4·9 (1·3) 4·8 (1·2) 5·2 (1·4) 4·8 (1·3) 0·008
Current smoker 73 (27%) 46 (18%) 65 (26%) 41 (17%) 0·005
Past smoker 117 (44%) 145 (56%) 135 (53%) 123 (51%) 0·051
Peripheral vascular 
disease
46 (17%) 45 (17%) 35 (14%) 42 (17%) 0·614
Extent of symptomatic 
carotid stenosis*
0·581
50–69% 37 (14%) 31 (12%) 29 (11%) 24 (10%)
70–99% 232 (86%) 236 (88%) 227 (89%) 220 (90%)
Extent of contralateral 
stenosis*
0·130
<50% 190 (71%) 170 (64%) 172 (68%) 153 (63%)
50–69% 34 (13%) 43 (16%) 40 (16%) 41 (17%)
70–99% 24 (9%) 40 (15%) 33 (13%) 39 (16%)
Occluded 20 (8%) 11 (4%) 10 (4%) 10 (4%)
Most recent ipsilateral 
event†
0·336
Amaurosis fugax 40 (15%) 42 (16%) 45 (18%) 34 (14%)
Transient ischaemic 
attack
100 (37%) 72 (27%) 80 (31%) 89 (37%)
Retinal infarct 8 (3%) 5 (2%) 5 (2%) 4 (2%)
Ischaemic hemispheric 
stroke
119 (44%) 142 (53%) 124 (49%) 114 (47%)
Unknown 2 (1%) 6 (2%) 2 (1%) 3 (1%)
Multiple ipsilateral 
symptoms before 
randomisation
120 (45%) 97 (36%) 93 (37%) 99 (41%) 0·154
Ipsilateral stroke before 
most recent ipsilateral 
event
42 (16%) 48 (18%) 29 (11%) 39 (16%) 0·194
Data are n (%) unless otherwise indicated. ARWMC=age-related white-matter changes. *Extent of stenosis measured 
by the method used in the North American Carotid Endarterectomy Trial10 at randomising centre. †If two events were 
reported on the same day, we counted the more serious of the two (stroke>retinal infarct>transient ischaemic 
attack>amaurosis fugax). 
Table: Baseline characteristics
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analyses described here were decided before any results 
were analysed.
The analyses were done for the following outcome 
measures: any stroke, non-disabling stroke, and disabling 
or fatal stroke. Data were analysed per protocol—ie, the 
analysis included only patients who received the allocated 
treatment as their ﬁ rst ipsilateral revascularisation 
procedure. Patients who received the alternative 
revascularisation procedure as their ﬁ rst treatment 
(cross-overs), or who received no revascularisation 
treatment, were excluded from this analysis. All outcome 
events occurring within 30 days after initiation of the 
ﬁ rst allocated treatment were included. 
Patients were dichotomised into two groups at the 
median value for the age-related white-matter changes 
score. The median was chosen as the cut-point for the 
analysis before doing any analyses to ensure equal-sized 
groups of patients for the comparisons and to avoid the 
risk of the bias introduced by selecting an optimum 
cut point after initial analysis of the data.17 The baseline 
characteristics in the two treatment groups were then 
compared according to whether their ARWMC score 
was lower than 7 versus 7 or greater using Pearson’s 
χ² test or analysis of variance. We compared the 30-day 
risk of the various outcome events between the two 
treatment groups using a Cox proportional hazards 
model. We estimated the cumulative incidences of the 
diﬀ erent outcome measures using Kaplan-Meier 
analysis and compared them using log-rank tests 
stratiﬁ ed by treatment with ARWMC score dichotomised 
at the median. All analyses were adjusted for age, sex, 
and vascular risk factors. We used SPSS (version 21) for 
all statistical analyses. 
ICSS is registered with controlled-trials.com, number 
ISRCTN 25337470. 
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Results
High-quality baseline brain imaging was available from 
1036 (61%) of 1649 patients enrolled in ICSS between May, 
2001, and October, 2008, in whom the allocated treatment 
was initiated as the ﬁ rst ipsilateral revascularisation 
procedure within 30 days of randomisation (ﬁ gure 1). Of 
these patients, 536 were allocated to treatment with carotid 
artery stenting and 500 were allocated to treatment with 
carotid endarterectomy. CT was analysed in 566 (55%) 
patients and MRI in 470 (45%) patients. Baseline 
characteristics were much the same between included 
patients and those who were excluded because of missing 
or inadequate imaging (data not shown).
The median ARWMC score at baseline was 7; patients 
with an ARWMC score of 7 or more were, on average, 
older and less likely to have had a CT scan only than 
those with an ARWMC score of less than 7 (table). 
Hypertension, hyper cholesterolaemia, current smoking, 
and the presence of cerebral infarcts on baseline imaging 
were associated with a higher ARWMC score. We 
detected no diﬀ erence in the proportion of patients 
receiving carotid artery stenting compared with carotid 
endarterectomy in the two groups, or in baseline 
characteristics between the two treatment groups (carotid 
stenting vs endarterectomy). 
In patients in the stenting group, we detected an 
increase in the risk of stroke in patients with an ARWMC 
score of 7 or more compared with those with an ARWMC 
Figure 2: 30-day cumulative incidence of stroke by severity of white-matter lesions
(A) any stroke, (B) non-disabling stroke, (C) fatal or disabling stroke. ARWMC=age-related white-matter changes. Error bars are SDs. 
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score of less than 7. The hazard ratio (HR) for any stroke 
was 2·76 (95% CI 1·17–6·51; p=0·021) and the hazard 
ratio for non-disabling stroke was 3·00 (1·10–8·36; 
p=0·031). There was a similar proportional increase in 
the risk of disabling or fatal stroke with ARWMC score of 
7 or more in patients who underwent carotid artery 
stenting, but the number of events available for analysis 
was smaller than available for the other stroke outcome 
clusters and the diﬀ erence was not statistically signiﬁ cant 
(HR 2·88, 0·61–13·6; p=0·181). By contrast with these 
ﬁ ndings, in the carotid endarterectomy group, there was 
no diﬀ erence in the risk of stroke between patients with a 
high versus low ARWMC score  (HR for any stroke 1·18, 
0·40–3·55; p=0·76; HR for non-disabling stroke 1·11, 
0·14–8·62; p=0·924; HR for disabling or fatal stroke 
1·41, 0·38–5·26, p=0·607).
In patients with an ARWMC score of less than 7, we 
detected no diﬀ erence in the risk of any of the stroke 
outcome clusters between the stenting and endarterectomy 
groups (ﬁ gure 2). By contrast, in patients with an ARWMC 
score of 7 or more, carotid artery stenting was associated 
with a higher risk of any stroke (HR 2·98, 1·29–6·93; 
p=0·011) and non-disabling stroke (6·34, 1·45–27·71; 
p=0·014) compared with carotid endarterectomy. The risk 
of fatal or disabling stroke in patients with an ARWMC 
score of 7 or more was not statistically signiﬁ cant between 
the two treatment groups (HR 1·56; 0·52–4·65; p=0·428). 
Discussion
Our results show that, in patients with symptomatic 
internal carotid artery stenosis, an increased severity of 
white-matter damage on CT or MRI is associated with an 
increased risk of procedural stroke. This increase in the 
risk of stroke seems to be restricted to patients treated 
with carotid artery stenting rather than with carotid 
endarterectomy. Our ﬁ ndings also show that the risk of 
stenting strongly depends on the severity of white-matter 
damage: the risk of stroke was similar between the two 
treatment groups in patients with less extensive white-
matter lesions (ARWMC score <7), but much higher for 
carotid artery stenting than for carotid endarterectomy in 
patients with more extensive white-matter lesions 
(ARWMC score ≥7).
We detected no statistically signiﬁ cant increase in the 
risk of a procedural outcome event with more severe 
ARWMC in the surgery group. This ﬁ nding is in contrast 
with ﬁ ndings from a similar study done in patients in 
North American Symptomatic Carotid Endarterectomy 
Trial (NASCET),14 which showed a near tripling in the rate 
of perioperative stroke or death in patients with widespread 
white-matter changes deﬁ ned as involving an entire 
region from the lateral ventricle to the cortex and a 
doubling of this risk in patients with white-matter changes 
deﬁ ned as restricted to the region adjoining the ventricles. 
However, the fact that the 30-day rate of stroke or death 
after carotid endarterectomy was 6·7% in NASCET, 
compared with only 3·4% in ICSS should be borne in 
mind.3,18 By contrast with the ﬁ ndings from NASCET, that 
we did not detect a signiﬁ cant increase in the 
periprocedural stroke risk in surgically treated patients 
with more severe white-matter disease is likely to reﬂ ect 
the improved outcome of surgery over the years. 
Findings from a previous ICSS MRI substudy19 showed 
that there is a much higher rate of small emboli detected 
on DWI MRI after carotid artery stenting than after 
carotid endarterectomy. One possible explanation for our 
ﬁ ndings is that a given number of emboli resulting from 
carotid artery stenting could be more likely to result in 
symptoms of stroke if pre-existing white-matter damage 
has reduced cerebrovascular reserve. White-matter 
changes are thought to be caused at least in part by 
chronic hypoperfusion, as the result of small and large 
vessel atherosclerotic disease that leads to chronic 
white-matter hypoperfusion and changes in the 
blood–brain barrier.9,20–24 White-matter lesions were 
associated with an increased risk of stroke in the present 
study and are a risk factor for ﬁ rst-ever and recurrent 
stroke in large population-based studies.25–27 A patient 
with chronic ischaemia of the brain might be more likely 
to develop infarction after subsequent ischaemic events.28 
Findings from a study using arterial spin-labelling MR 
perfusion showed that patients with diﬀ use conﬂ uent 
white-matter hyperintensities had about 20% lower 
cerebral blood ﬂ ow measurements than patients with 
punctiform or beginning conﬂ uent white-matter 
hyperintensities.29 The investigators detected not only a 
reduction of subcortical white matter and deep-grey 
matter but also of cortical grey matter and global cerebral 
blood ﬂ ow values in patients with diﬀ use conﬂ uent 
white-matter hyperintensities; the investigators regarded 
these ﬁ ndings as evidence that such patients have a 
generalised cerebrovascular disease process rather than 
one conﬁ ned to lesions. In keeping with this suggestion, 
in a series of 70 patients with severe symptomatic carotid 
stenosis undergoing carotid endarterectomy, the volume 
of white-matter lesions was associated with the need for 
intraoperative shunting during carotid endarterectomy, 
an index of impaired cerebral haemodynamics.30 
We hypothesise, therefore, that the patients in our study 
with more extensive white-matter lesions did not have 
the cerebrovascular reserve and resilience to cope with 
further ischaemic events. 
Another possible explanation for our ﬁ ndings is that 
patients with more extensive white-matter lesions are 
more likely to have unstable plaque, making them more 
vulnerable to embolisation during stent insertion. 
One study of 57 patients having carotid endarterectomy 
for symptomatic carotid stenosis reported that the number 
of white-matter lesions before surgery was associated with 
the histological ﬁ nding of unstable plaque.31 Evidence also 
exists that patients with white-matter lesions have a 
prothrombotic state and endothelial dysfunction that 
might make them more vulnerable to embolisation 
during carotid artery stenting.32,33 
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Another possibility is that instead of being a risk factor 
in its own right, the severity of white-matter disease 
identiﬁ ed on brain imaging is a marker of the overall 
eﬀ ects of individual cardiovascular risk factors.13 In their 
meta-analysis of the data pooled from the three European-
based randomised trials, Bonati and colleagues6 noted 
that carotid stenting had a higher procedural risk than 
endarter ec tomy only in patients older than 70 years. A 
meta-analysis of all the published trials has conﬁ rmed 
these ﬁ ndings.5 Bonati and colleagues6 argued that this 
association with age might be due to an increased 
atherosclerotic burden and tortuosity of the aortic arch, 
with age putting the patients at increased risk of 
dislodgement of plaque debris. Although these 
arguments might explain part of the association of risk of 
carotid artery stenting with increasing age, our ﬁ ndings 
show an association between the severity of white-matter 
damage and risk of stroke after correction for age, 
suggesting that increasing age is not the only explanation 
for the increased risk.
Several patients randomly allocated in ICSS were 
excluded from analysis because the original baseline brain 
images were not available or the images were of 
inadequate quality for analysis. However, the baseline 
characteristics of the included patients were not diﬀ erent 
to those excluded from the study and were well matched 
between the treatment groups; thus selection bias is 
unlikely. Nevertheless, the sample size and number of 
outcome events in each group were smaller than in the 
entire ICSS cohort, limiting the power of the comparison.
CT was used in 55% of patients to assess the extent of 
ARWMC, and MRI was used in 45%. Although MRI is 
more sensitive than CT in detecting small punctate 
white-matter lesions (corresponding to grade 1 lesions of 
the rating scale we used), and there is inevitable 
variability in sensitivity to white-matter lesions between 
diﬀ erent scanners, there is good agreement between CT 
and MRI in detection of conﬂ uent and diﬀ use 
white-matter lesions (corresponding to grade 2 and 
3 lesions of the rating scale).34 The inherent increased 
sensitivity of MRI could have led to higher ARWMC 
score in patients with MRI rather than CT. However, the 
proportion of patients who had a CT scan only in the 
group randomised to stenting was similar to that in the 
group randomised to surgery (285 of 536 vs 281 of 501; 
p=0·35) and therefore the diﬀ erences in baseline 
imaging technique do not explain the diﬀ erence between 
the two arms of the trial. Moreover, clinically relevant, 
more extensive white-matter lesions shown in our study 
to be a risk factor for stenting are unlikely to have been 
missed by using CT. 
A strength of our analysis is that we used a 
semi-quantitative analysis of white-matter lesions using 
two investigators masked to clinical details who rated all 
images by consensus. However, because not all images 
were available in digital format, and most part ici pants did 
not have volumetric (three-dimensional) T2-weighted or 
FLAIR images, we were not able to use auto-
mated or semi-automated quantitative measurements of 
white-matter lesion volume. 
As can be expected from the pathophysiology of 
white-matter disease, presence of cerebral infarcts at base-
line, hypertension, current smoking, and raised cholesterol 
concentrations at baseline were more frequent in patients 
with severe age-related white-matter disease. The analysis 
took into account these vascular risk factors and thus 
diﬀ erences in underlying risk factor proﬁ les in patients 
with high ARWMC scores compared with those with low 
ARWMC scores are unlikely to have introduced bias.
Our ﬁ ndings suggest that the presence of white-matter 
disease on brain imaging should be taken into account 
when selecting patients for carotid revascularisation 
(panel). Carotid artery stenting should be avoided in 
patients with more severe white-matter disease, but might 
be an acceptable alternative to carotid endarterectomy in 
patients with no or mild disease. Future studies of carotid 
revascularisation should incorporate plaque imaging and 
measures of cerebral haemodynamics before treatment.
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Panel: Research in context 
Systematic review
We searched Medline for articles published in any language with the search terms “carotid 
stenosis”, “endarterectomy”, “stenting”, “leukoaraiosis”, and “white matter” to identify 
publications reporting the eﬀ ect of white-matter lesions seen on brain imaging on the 
periprocedural risk of stroke associated from revascularisation of carotid stenosis by carotid 
endarterectomy or carotid artery stenting. Our last search was done on April 28, 2013. 
We identiﬁ ed only one article reporting a doubling of 30-day perioperative risk of stroke or 
death in patients with leukoaraiosis on brain CT treated by carotid endarterectomy in the 
North American Symptomatic Carotid Endarterectomy Trial (NASCET),14 which included 
2618 patients with carotid stenosis and was completed 20 years ago. We identiﬁ ed no 
publications reporting the eﬀ ect of white-matter changes on the periprocedural risk of 
stenting. One publication reported that in a series of 70 patients the volume of 
white-matter lesions correlated with the need for intraoperative shunting during carotid 
endarterectomy, an index of impaired cerebral haemodynamics.30 Another publication 
reported that the number of white-matter lesions before surgery was associated with the 
histological ﬁ nding of unstable plaque in 57 patients having carotid endarterectomy for 
symptomatic carotid stenosis.31 A meta-analysis of the randomised trials comparing carotid 
endarterectomy with carotid artery stenting showed a higher 30 day risk of stroke after 
carotid artery stenting compared with carotid endarterectomy, but the eﬀ ect of 
white-matter lesions on this comparison was not known.5 
Interpretation
Our results indicate that the presence of white-matter lesions on brain imaging should be 
taken into account when selecting patients for carotid revascularisation. Carotid artery 
stenting should be avoided in patients with more extensive white-matter lesions, but 
might be an acceptable alternative to carotid endarterectomy in patients with less 
extensive lesions. Future studies of carotid revascularisation should incorporate plaque 
imaging and measures of cerebral haemodynamics before treatment.
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